Stocks · News reference
NuCana (NASDAQ:NCNA) will report on Q2 2026.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Read original at benzingaNuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster
Read original at benzinga